More Tarceva Phase III trials start

OSI Pharmaceuticals (OSIP) said Phase III trials of its Tarceva ( OSI-774) epidermal growth factor receptor ( EGFR) antagonist to treat metastatic pancreatic cancer and refractory lung cancer have started. Both studies are co-sponsored by the National Cancer Institute of Canada Clinical Trials Group. Tarceva is being developed as part of a 3-way alliance with Genentech (DNA) and Roche (SWX:ROCZ). ...